Brokers Set Expectations for Pear Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:PEAR)

Pear Therapeutics, Inc. (NASDAQ:PEAR – Get Rating) – Research analysts at Chardan Capital boosted their FY2023 earnings per share estimates for shares of Pear Therapeutics in a report issued on Monday, April 3rd. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings per share of ($0.56) for the year, up from […]

Related Keywords

Corey Mccann ,Manufacturers Life Insurance Company ,Pear Therapeutics Inc ,Sg Americas Securities ,Verdence Capital Advisors ,Credit Suisse Group ,Nasdaq ,Pear Therapeutics Company Profile ,Daiwa Securities Group Inc ,Pear Therapeutics ,Get Rating ,Chardan Capital ,Pear Therapeutic ,Suisse Group ,Securities Group ,Capital Advisors ,Pear Therapeutics Daily ,Nasdaq Pear ,Pear ,Medical ,Earnings Estimates ,